Compare GWH & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWH | CVM |
|---|---|---|
| Founded | 2011 | 1983 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 32.4M |
| IPO Year | N/A | 1996 |
| Metric | GWH | CVM |
|---|---|---|
| Price | $1.14 | $3.20 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.25 | N/A |
| AVG Volume (30 Days) | ★ 300.6K | 57.1K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | $33.99 | N/A |
| Revenue Next Year | $1,328.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.76 | $0.23 |
| 52 Week High | $13.87 | $13.48 |
| Indicator | GWH | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 37.82 |
| Support Level | $1.08 | $3.18 |
| Resistance Level | $1.24 | $4.84 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 34.37 | 2.50 |
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. It develops and manufactures long-duration energy storage systems based on iron flow battery technology. The company's batteries use earth-abundant materials, including iron, salt, and water, and are designed for high cycle life and recyclability. It operates as a single business operating segment, which includes all activities related to the design, engineering, and manufacturing of the company's long duration energy storage products. The company's revenue is derived from the sale of its energy storage products and from service contracts.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.